PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Completed

Conditions: Renal Cell Cancer
Renal Cell Carcinoma
Kidney Cancer
Kidney Neoplasms
Renal Cancer
Cancer of Kidney
Cancer of the Kidney

First Posted Date: 2022-05-05

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 1112

Registration Number: NCT05363072

Locations: 🇫🇮
Pfizer Finland, Helsinki, Finland

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Phase 1

Recruiting

Conditions: Melanoma
Non-Small-Cell Lung Cancer
Thyroid Cancer
Glioma

Interventions: Drug: PF-07799933
Drug: binimetinib
Biological: cetuximab

First Posted Date: 2022-05-02

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 156

Registration Number: NCT05355701

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 33 locations

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07284890 Treatment A
Drug: PF-07284890 Treatment B
Drug: PF-07284890 Treatment C

First Posted Date: 2022-04-27

Last Posted Date: 2024-03-15

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05349864

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

Phase 3

Active, not recruiting

Conditions: Vaso-occlusive Crisis
Sickle Cell Disease
Vaso-occlusive Pain Episode in Sickle Cell Disease

Interventions: Drug: Inclacumab

First Posted Date: 2022-04-27

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 123

Registration Number: NCT05348915

Locations: 🇺🇸
Brigham And Woman's Hospital, Boston, Massachusetts, United States
🇺🇸
University of South Alabama Children's and Women's Hospital, Mobile, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 17 locations

A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332/ritonavir

First Posted Date: 2022-04-21

Last Posted Date: 2024-10-08

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT05339334

Locations: 🇨🇳
Huashan Hospital,Fudan University, Shanghai, Shanghai, China

A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Phase 4

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2022-04-14

Last Posted Date: 2024-04-26

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT05329259

Locations: 🇮🇳
Calcutta School of Tropical Medicine, Kolkata, WEST Bengal, India
🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳
Jawahar Lal Nehru Medical College, Ajmer, Rajasthan, India

and more 2 locations

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Apixaban

First Posted Date: 2022-04-11

Last Posted Date: 2024-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 193565

Registration Number: NCT05321810

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Lenalidomide

First Posted Date: 2022-04-07

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 760

Registration Number: NCT05317416

Locations: 🇯🇵
University Hospital,Kyoto Prefectural University of Medicine, Kyoto, Japan
🇪🇸
Hospital La Princesa, Madrid, Spain
🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain

and more 217 locations

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Phase 3

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: RSVpreF Vaccine
Other: Placebo
Biological: Seasonal Inactivated Influenza Vaccine

First Posted Date: 2022-03-29

Last Posted Date: 2023-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 1471

Registration Number: NCT05301322

Locations: 🇦🇺
AusTrials - Taringa, Taringa, Queensland, Australia
🇦🇺
Paratus Clinical Research Brisbane, Albion, Queensland, Australia
🇦🇺
John Hunter Hospital, New Lambton Heights, New South Wales, Australia

and more 27 locations

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

Phase 4

Recruiting

Conditions: Myocarditis

Interventions: Diagnostic Test: Cardiac Imaging

First Posted Date: 2022-03-25

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 300

Registration Number: NCT05295290

Locations: 🇺🇸
Children'S Hospitals & Clinics of Minn, Minneapolis, Minnesota, United States
🇺🇸
Childrens Mercy Kansas City, Kansas City, Missouri, United States
🇺🇸
Children's of Alabama, Birmingham, Alabama, United States

and more 29 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy